JP7722990B2 - アミロイド沈着物を標的化するための修飾免疫グロブリン - Google Patents

アミロイド沈着物を標的化するための修飾免疫グロブリン

Info

Publication number
JP7722990B2
JP7722990B2 JP2022528305A JP2022528305A JP7722990B2 JP 7722990 B2 JP7722990 B2 JP 7722990B2 JP 2022528305 A JP2022528305 A JP 2022528305A JP 2022528305 A JP2022528305 A JP 2022528305A JP 7722990 B2 JP7722990 B2 JP 7722990B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022528305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502968A5 (enExample
JP2023502968A (ja
Inventor
ジョナサン・エス・ウォール
ジェームズ・エス・フォスター
スペンサー・ガズリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of JP2023502968A publication Critical patent/JP2023502968A/ja
Publication of JP2023502968A5 publication Critical patent/JP2023502968A5/ja
Priority to JP2025104401A priority Critical patent/JP2025134876A/ja
Application granted granted Critical
Publication of JP7722990B2 publication Critical patent/JP7722990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
JP2022528305A 2019-11-15 2020-11-13 アミロイド沈着物を標的化するための修飾免疫グロブリン Active JP7722990B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025104401A JP2025134876A (ja) 2019-11-15 2025-06-20 アミロイド沈着物を標的化するための修飾免疫グロブリン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962936002P 2019-11-15 2019-11-15
US62/936,002 2019-11-15
US202063074912P 2020-09-04 2020-09-04
US63/074,912 2020-09-04
PCT/US2020/060596 WO2021097360A1 (en) 2019-11-15 2020-11-13 Modified immunoglobulins for targeting amyloid deposits

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025104401A Division JP2025134876A (ja) 2019-11-15 2025-06-20 アミロイド沈着物を標的化するための修飾免疫グロブリン

Publications (3)

Publication Number Publication Date
JP2023502968A JP2023502968A (ja) 2023-01-26
JP2023502968A5 JP2023502968A5 (enExample) 2023-11-20
JP7722990B2 true JP7722990B2 (ja) 2025-08-13

Family

ID=75912899

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022528305A Active JP7722990B2 (ja) 2019-11-15 2020-11-13 アミロイド沈着物を標的化するための修飾免疫グロブリン
JP2025104401A Pending JP2025134876A (ja) 2019-11-15 2025-06-20 アミロイド沈着物を標的化するための修飾免疫グロブリン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025104401A Pending JP2025134876A (ja) 2019-11-15 2025-06-20 アミロイド沈着物を標的化するための修飾免疫グロブリン

Country Status (11)

Country Link
US (5) US20220411489A1 (enExample)
EP (1) EP4058479A4 (enExample)
JP (2) JP7722990B2 (enExample)
KR (1) KR20220113950A (enExample)
CN (1) CN115298214A (enExample)
AU (1) AU2020385183A1 (enExample)
BR (1) BR112022009273A2 (enExample)
CA (1) CA3158206A1 (enExample)
IL (1) IL292903B2 (enExample)
MX (1) MX2022005850A (enExample)
WO (1) WO2021097360A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115298214A (zh) 2019-11-15 2022-11-04 田纳西大学研究基金会 用于靶向淀粉样蛋白沉积物的经修饰的免疫球蛋白
KR20230144525A (ko) * 2020-12-04 2023-10-16 유니버시티 오브 테네시 리서치 파운데이션 아밀로이드 질환을 진단하기 위한 방법
CA3217756A1 (en) * 2021-05-05 2022-11-10 Jonathan S. Wall Peptide-fc fusions for treating amyloid disorders
JP2024521082A (ja) 2021-05-18 2024-05-28 ユニバーシティ オブ テネシー リサーチ ファウンデーション アミロイド障害を処置するための抗体－ペプチド融合タンパク質
KR20240055101A (ko) * 2021-09-14 2024-04-26 시일럼 바이오사이언시즈, 인크. 다발성 골수종의 치료 방법
US20250019425A1 (en) * 2021-11-12 2025-01-16 Adrx, Inc. Transthyretin (ttr) monomer binding antibodies
JP2025515741A (ja) * 2022-05-11 2025-05-20 アレクシオン ファーマシューティカルズ， インコーポレイテッド 高感度ビオチン化ペプチド結合ｅｌｉｓａアッセイ
WO2024050478A1 (en) * 2022-09-02 2024-03-07 University Of Tennessee Research Foundation Chimeric antigen receptors for removal of amyloid
AU2024339036A1 (en) 2023-09-07 2026-03-12 University Of Tennessee Research Foundation Method for diagnosing amyloid diseases
WO2025212955A1 (en) 2024-04-05 2025-10-09 University Of Tennessee Research Foundation Method for diagnosing amyloid diseases
WO2026055521A1 (en) * 2024-09-06 2026-03-12 University Of Tennessee Research Foundation Antibody-peptide fusion proteins for treating amyloid disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110300141A1 (en) 2005-06-17 2011-12-08 Balu Chakravarthy Novel Alphabeta-Binding protein and its peptide derivatives and uses thereof
JP2012246299A (ja) 2003-06-30 2012-12-13 Tel Aviv Univ Future Technology Development Lp アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法
JP2017528449A (ja) 2014-08-26 2017-09-28 ユニバーシティ オブ テネシー リサーチ ファウンデーション アミロイドーシスのための標的化免疫療法
WO2018138709A1 (en) 2017-01-30 2018-08-02 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
WO2019027721A2 (en) 2017-08-01 2019-02-07 The Trustees Of Columbia University In The City Of New York METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DISEASE DISEASES

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
WO1995015982A2 (en) * 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE69942274D1 (de) * 1998-05-21 2010-06-02 Univ Tennessee Res Foundation Methoden zur amyloidentfernung mit anti-amyloid-antikörper
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7312318B2 (en) * 2002-03-01 2007-12-25 Immunomedics, Inc. Internalizing anti-CD74 antibodies and methods of use
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
EP2125893A2 (en) * 2007-01-23 2009-12-02 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
DK2237803T3 (en) * 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
WO2011119608A1 (en) 2010-03-26 2011-09-29 University Of Tennessee Research Foundation Peptides that specifically target amyloid deposits
US20140079691A1 (en) 2012-09-20 2014-03-20 Anaptysbio, Inc. Thermostable antibody framework regions
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
US11530257B2 (en) * 2017-06-29 2022-12-20 The Trustees Of Columbia University In The City Of New York Chimeric antibodies for treatment of amyloid deposition diseases
WO2019241216A1 (en) 2018-06-14 2019-12-19 Bioatla, Llc Multi-specific antibody constructs
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
CN115298214A (zh) 2019-11-15 2022-11-04 田纳西大学研究基金会 用于靶向淀粉样蛋白沉积物的经修饰的免疫球蛋白
JP2024521082A (ja) 2021-05-18 2024-05-28 ユニバーシティ オブ テネシー リサーチ ファウンデーション アミロイド障害を処置するための抗体－ペプチド融合タンパク質

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012246299A (ja) 2003-06-30 2012-12-13 Tel Aviv Univ Future Technology Development Lp アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法
US20110300141A1 (en) 2005-06-17 2011-12-08 Balu Chakravarthy Novel Alphabeta-Binding protein and its peptide derivatives and uses thereof
JP2017528449A (ja) 2014-08-26 2017-09-28 ユニバーシティ オブ テネシー リサーチ ファウンデーション アミロイドーシスのための標的化免疫療法
WO2018138709A1 (en) 2017-01-30 2018-08-02 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
WO2019150183A1 (en) 2017-01-30 2019-08-08 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
WO2019027721A2 (en) 2017-08-01 2019-02-07 The Trustees Of Columbia University In The City Of New York METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DISEASE DISEASES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Frontiers in Immunology，2017年，Vol.8, Article 1082，pp.1-14
PNAS，2018年，Vol.115, No.46，pp.E10839-E10848

Also Published As

Publication number Publication date
WO2021097360A1 (en) 2021-05-20
CN115298214A (zh) 2022-11-04
MX2022005850A (es) 2022-08-15
US12030934B2 (en) 2024-07-09
CA3158206A1 (en) 2021-05-20
US12264195B2 (en) 2025-04-01
US20250368729A1 (en) 2025-12-04
US12157765B2 (en) 2024-12-03
AU2020385183A1 (en) 2022-05-26
EP4058479A4 (en) 2024-02-28
US20240294621A1 (en) 2024-09-05
US20240294620A1 (en) 2024-09-05
IL292903B2 (en) 2026-04-01
IL292903A (en) 2022-07-01
US20220411489A1 (en) 2022-12-29
IL292903B1 (en) 2025-12-01
US20230265178A1 (en) 2023-08-24
BR112022009273A2 (pt) 2022-10-04
KR20220113950A (ko) 2022-08-17
JP2025134876A (ja) 2025-09-17
EP4058479A1 (en) 2022-09-21
JP2023502968A (ja) 2023-01-26

Similar Documents

Publication Publication Date Title
JP7722990B2 (ja) アミロイド沈着物を標的化するための修飾免疫グロブリン
AU2014204465B2 (en) Humanized antibodies to amyloid beta
JP2024088689A (ja) 抗ｐｈｆ－タウ抗体及びその使用
JP7101927B2 (ja) 抗トランスサイレチン抗体
AU2017259039B2 (en) Antibodies recognizing tau
US20190083616A1 (en) Targeting immunotherapy for amyloidosis
BR112021008624A2 (pt) Anticorpos que reconhecem tau
US20250101090A1 (en) Antibody-peptide fusion proteins for treating amyloid disorders
JP2022529344A (ja) 治療及び診断のための新規分子
AU2020330307A1 (en) Complement C2 binding proteins and uses thereof
US10584175B2 (en) FN14-binding proteins and uses thereof
EA048681B1 (ru) Модифицированные иммуноглобулины для нацеливания на амилоидные отложения
JP2018508193A (ja) メディンを認識する抗体
EA051549B1 (ru) Слитые белки антитело-пептид для лечения амилоидных дистрофий
EA047896B1 (ru) Антитела, распознающие тау
HK40024078A (en) Human-derived anti-transthyretin antibody, polynucleotide, vector and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250620

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250731

R150 Certificate of patent or registration of utility model

Ref document number: 7722990

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150